常熟市4家医院2014年至2017年质子泵抑制剂应用分析  

Application of Proton Pump Inhibitors in Four Hospitals in Changshu City from 2014 to 2017

作　　者：谭建中[1] 吴晓明[1] 殷卫清[2] 周晨霞[3] 鱼胜 TAN Jianzhong;WU Xiaoming;YIN Weiqing;ZHOU Chenxia;YU Sheng(Changshu Traditional Chinese Mennize Hospitnl, Changshu, Jiangsu, Chinn 2.15500;The First People's Hospitnl of Changshu City, Changshu,Jiangsu, China 215500;The Second, People s HospZnl of Changshu Cay, Changshu, Jiangsu, Chinn 215550;The Fifth People' s Hospitnl of Changshu City, Changshu, Jiangsh, Chinn 215500)

机构地区：[1]江苏省常熟市中医院,江苏常熟215500 [2]江苏省常熟市第一人民医院,江苏常熟215500 [3]江苏省常熟市第二人民医院,江苏常熟215500 [4]江苏省常熟市第五人民医院,江苏常熟215500

出　　处：《中国药业》2019年第17期96-96,I0002-I0005,共5页China Pharmaceuticals

基　　金：江苏省药学会—天晴临床药学基金科研项目[Q2018136]

摘　　要：目的了解江苏省常熟市4家二级甲等以上综合性医院质子泵抑制剂的临床应用情况,促进合理应用。方法采用回顾性调查方法对质子泵抑制剂的销售金额、年增长率及构成比、用药频度(DDDs)、排序比(B/A)和日均费用(DDC)等进行分析。结果4家医院2014年至2017年药品销售金额增长率呈下降趋势,较上年的增长率分别为4.52%,2.75%,-5.87%,而质子泵抑制剂占当年药品销售金额的百分比分别为5.85%,5.61%,5.73%,5.83%,呈现稳定态势;4年各家医院口服用质子泵抑制剂销售金额构成比、DDDs构成比、DDC值,医院甲为59.75%,67.03%,4.87元,医院乙为22.86%,18.81%,6.64元,医院丙为12.60%,10.62%,6.48元,医院丁为4.79%,3.54%,7.38元;注射用质子泵抑制剂销售金额构成比、DDDs构成比、DDC值分别为医院甲为64.80%,63.28%,61.02元,医院乙为16.71%,20.24%,49.20元,医院丙为13.99%,13.06%,63.81元,医院丁为4.50%,3.42%,78.43元。泮托拉唑(注射)、雷贝拉唑(口服)、奥美拉唑(注射)销售金额一直排名前3,DDDs以奥美拉唑(口服)列首位,其次为雷贝拉唑(口服)、兰索拉唑(口服);DDC各年度排首位的为艾司奥美拉唑(注射)。结论质子泵抑制剂临床应用基本合理,但应重视用药合理性、安全性和经济性。Objective To understand the clinical application of proton pump inhibitors in four general hospitals above grade-Ⅱ class A in Changshu City,Jiangsu Province,and to provide reference for the rational application of proton pump inhibitors. Methods The sales amount,annual growth rate and composition ratio,DDDs,B/A,and DDC of proton pump inhibitors were analyzed by retrospective survey method. Results The growth rates of drug sales in four hospitals showed a downward trend from 2014 to 2017,the growth rates were 4. 52%,2. 75% and-5. 87% compared with the previous year. Proton pump inhibitors accounted for 5. 85%,5. 61%,5. 73%and 5. 83% in the year of drug sales,which showed a stable trend. In the past four years,the composition ratio of sales amount,composition ratio of DDDs and DDC of oral proton pump inhibitors were 59. 75%,67. 03%,4. 87 Yuan in hospital A,22. 86%,18. 81%,6. 64 Yuan in hospital B,12. 60%,10. 62% and 6. 48 Yuan in hospital C,4. 79%,3. 54% and 7. 38 Yuan in hospital D. The composition ratio of sales amount,composition ratio of DDDs and DDC of proton pump inhibitors for injection were 64. 80%,63. 28% and61. 02 Yuan in hospital A,16. 71%,20. 24% and 49. 20 Yuan in hospital B,13. 99%,13. 06%,63. 81 Yuan in hospital C,4. 50%,3. 42% and 78. 43 Yuan in hospital D. The sales amount of pantoprazole( injection),rabeprazole( oral),omeprazole( injection) has been ranked the top three,the DDDs of omeprazole( oral) ranked first,followed by rabeprazole( oral),lansoprazole( oral). Esomeprazole( injection)ranked first in DDC in each year. Conclusion The clinical application of proton pump inhibitors is reasonable,but attention should be paid to the rationality,safety and economy of drug use.

关 键 词：质子泵抑制剂 销售金额 用药频度 日均费用 用药分析 合理用药 

分 类 号：R969.3[医药卫生—药理学] R975.2[医药卫生—药学]